In the phase 3 OptiTROP-Lung06 study, which was run by Kelun in 455 Chinese patients, sac-TMT reduced the risk of disease ...

Sofe-m was acquired by Lilly as part of its 2023 takeover of French biotech Mablink Bioscience and its PSARLink ADC ...

VOLGA was conducted in patients with MIBC ineligible or unwilling to take platinum-based chemotherapy, who received PD-L1 inhibitor Imfinzi (durvalumab) before and after surgery to remove the tumour, ...

Nubeqa is a key growth product for Bayer, with sales up around 60% to €1.63 billion in the first half of this year from its ...

The full look at the results of the DeLLphi-305 study of Imdelltra (tarlatamab) and Imfinzi (durvalumab) as first-line maintenance therapy for extensive-stage SCLC (ES-SCLC) whose disease had not ...

Moderna and MSD have shared keenly anticipated results for their melanoma cancer vaccine, ahead of a presentation at ESMO ...

In the new guidance, the agency has concluded that AI-Rad Companion Prostate MR, DeepHealth Prostate, ProstatID, Prostate ...

Two drugs hoping to muscle in Amgen's first-to-market DLL3-targeting drug Imdelltra – from Zai Lab and Ideaya – have new ...

A drug at the heart of Johnson & Johnson's $3 billion takeover of Halda last year, JNJ-6143, has shown promise in an ...

Waterhouse is due to take the helm of CSL on 1st February next year, around a year after Paul McKenzie abruptly departed the ...

The most consequential changes in cancer biology can often occur before they become visible on a scan. Yet, modern cancer ...

An overview of the NHS’s AI-Assisted Discharge Summarisation (AADS) project and what it takes to move AI beyond the pilot ...